Clinical Trials
5 trialsNCT02907099 2025-02-19
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01838395 2024-09-19
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
BioLineRx, Ltd.
Phase 2 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT02639559 2023-11-07
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT02763384 2023-10-31
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Washington University School of Medicine
Phase 2 Terminated